Published in Volume
102, Issue 3 (August 1, 1998)
J Clin Invest. 1998;102(3):465–472.
doi:10.1172/JCI3145.
Copyright ©
1998, The American Society for
Clinical Investigation.
Research Article
Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer.
D A Arenberg, M P Keane, B DiGiovine, S L Kunkel, S B Morris, Y Y Xue, M D Burdick, M C Glass, M D Iannettoni and R M Strieter
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109-0642, USA.
Published August 1, 1998
We report here the role of the CXC chemokine, epithelial neutrophil activating peptide (ENA-78), as an angiogenic factor in human non-small cell lung cancer (NSCLC). In freshly isolated human specimens of NSCLC, elevated levels of ENA-78 were found that strongly correlated with the vascularity of the tumors. In a SCID mouse model of human NSCLC tumorigenesis, expression of ENA-78 in developing tumors correlated with tumor growth in two different NSCLC cell lines. Furthermore, passive immunization of NSCLC tumor-bearing mice with neutralizing anti-ENA-78 antibodies reduced tumor growth, tumor vascularity, and spontaneous metastases, while having no effect on the proliferation of NSCLC cells either in vitro or in vivo. These findings suggest that ENA-78 is an important angiogenic factor in human NSCLC.
